{"id":10285,"date":"2026-02-20T17:03:44","date_gmt":"2026-02-20T17:03:44","guid":{"rendered":"https:\/\/mdxcro.com\/fda-qmsr\/"},"modified":"2026-07-23T11:57:04","modified_gmt":"2026-07-23T11:57:04","slug":"fda-qmsr-regulacion-sistema-gestion-calidad","status":"publish","type":"post","link":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/","title":{"rendered":"FDA QMSR: c\u00f3mo el cambio normativo de 2026 transforma las auditor\u00edas MDSAP y las inspecciones de cumplimiento de la FDA"},"content":{"rendered":"<div class=\"wp-block-post-author-name\">Joana Martins<\/div>\n<p class=\"wp-block-paragraph\">El 2 de febrero de 2026, la <a href=\"https:\/\/www.fda.gov\/medical-devices\/postmarket-requirements-devices\/quality-management-system-regulation-qmsr\"><strong>Food and Drug Administration (FDA) <\/strong>de EE. UU. implement\u00f3 la nueva <strong>Quality Management System Regulation (QMSR)<\/strong><\/a>, sustituyendo formalmente a la anterior Quality System Regulation (21 CFR Part 820). Con esta transici\u00f3n, la FDA incorpor\u00f3 por referencia la ISO 13485:2016 a la legislaci\u00f3n estadounidense e introdujo un nuevo modelo de inspecci\u00f3n en el marco del Compliance Program 7382.850. <\/p>\n\n<p class=\"wp-block-paragraph\">This article focuses on that second question. It explains how to structure a QMSR gap analysis, which areas almost always reveal gaps in practice, particularly for <a href=\"https:\/\/mdxcro.com\/fda-ivd-regulation\/\">IVD<\/a> and <a href=\"https:\/\/mdxcro.com\/fda-companion-diagnostics\/\" type=\"post\" id=\"11221\">companion diagnostic<\/a> manufacturers, and what FDA inspectors are finding in the first wave of QMSR inspections.<\/p>\n\n<p class=\"wp-block-paragraph\">The insights below draw directly on MDx CRO&#8217;s quality and regulatory affairs experience supporting IVD manufacturers through QMSR readiness assessments.<\/p>\n\n<blockquote class=\"wp-block-quote has-white-frost-background-color has-background has-medium-font-size is-layout-flow wp-block-quote-is-layout-flow\" style=\"border-left-color:var(--wp--preset--color--blue);border-left-width:6px\">\n<p class=\"wp-block-paragraph\"><strong>Key point: <\/strong>ISO 13485 certification does not equal QMSR compliance. FDA-specific requirements remain fully enforceable, and under QMSR, inspectors now access records they previously could not.<\/p>\n<\/blockquote>\n\n<nav id=\"auto-toc\" style=\"background:#f4f7fb; border-left:4px solid #1a4f8a; padding:20px 24px; margin:28px 0; border-radius:4px; display:none;\">\n  <p style=\"font-weight:700; margin:0 0 12px 0; font-size:15px;\">In this article<\/p>\n  <ol id=\"toc-list\" style=\"margin:0; padding-left:20px; line-height:2;\"><\/ol>\n<\/nav>\n\n<script>\ndocument.addEventListener(\"DOMContentLoaded\", function() {\n  \/\/ 1. Seleccionamos el contenedor del \u00edndice y la lista donde ir\u00e1n los enlaces\n  const tocContainer = document.getElementById(\"auto-toc\");\n  const tocList = document.getElementById(\"toc-list\");\n  \n  \/\/ 2. Buscamos todos los H2 y H3 dentro del contenido del art\u00edculo\n  \/\/ Nota: Si tus subt\u00edtulos est\u00e1n dentro de una clase espec\u00edfica (ej. .entry-content), \n  \/\/ puedes cambiar 'h2, h3' por '.entry-content h2, .entry-content h3'\n  const headings = document.querySelectorAll(\"h2, h3\");\n  \n  \/\/ Si no hay subt\u00edtulos, el \u00edndice no se muestra\n  if (headings.length === 0) return;\n\n  headings.forEach((heading, index) => {\n    \/\/ 3. Si el H2\/H3 no tiene un ID, le creamos uno autom\u00e1tico basado en el texto\n    if (!heading.id) {\n      heading.id = \"seccion-\" + index;\n    }\n\n    \/\/ 4. Creamos el elemento de la lista (li) y el enlace (a)\n    const li = document.createElement(\"li\");\n    const a = document.createElement(\"a\");\n    \n    a.href = \"#\" + heading.id;\n    a.textContent = heading.textContent;\n    a.style.textDecoration = \"none\";\n    a.style.color = \"#1a4f8a\"; \/\/ Color azul como tu borde\n\n    \/\/ 5. Si es un H3, le damos una sangr\u00eda (indentaci\u00f3n) para que se note la jerarqu\u00eda\n    if (heading.tagName.toLowerCase() === \"h3\") {\n      li.style.marginLeft = \"20px\";\n      li.style.listStyleType = \"circle\"; \/\/ Cambia el vi\u00f1eta para diferenciarlo\n    }\n\n    li.appendChild(a);\n    tocList.appendChild(li);\n  });\n\n  \/\/ 6. Hacemos visible el \u00edndice ahora que ya tiene contenido\n  tocContainer.style.display = \"block\";\n});\n<\/script>\n\n<h2 class=\"wp-block-heading\"><strong>Why the FDA QMSR Matters Beyond the February 2026 Deadline<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">The February deadline was the starting point, not the finish line. FDA&#8217;s Compliance Program 7382.850 is now the active inspection model. Manufacturers operating under the assumption that QMSR readiness was a one-time transition exercise are exposed to a different enforcement environment than the one they prepared for.<\/p>\n\n<p class=\"wp-block-paragraph\">Under the former QSR model, inspections used QSIT subsystem checklists. Under QMSR, investigators evaluate how quality processes function as an integrated lifecycle framework, not whether each subsystem satisfies an individual checklist. That structural shift changes what inspectors look for and what they find.<\/p>\n\n<blockquote class=\"wp-block-quote has-white-frost-background-color has-background has-medium-font-size is-layout-flow wp-block-quote-is-layout-flow\" style=\"border-left-color:var(--wp--preset--color--blue);border-left-width:6px\">\n<p class=\"wp-block-paragraph\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">Inspection change: <\/mark><\/strong>FDA inspectors can now access internal audit reports, management reviews, and supplier audits. Under the previous QSR model, these records were largely outside inspection scope. Many manufacturers are unaware of this shift and have not reviewed the quality or completeness of these documents with inspection readiness in mind.<\/p>\n<\/blockquote>\n\n<h2 class=\"wp-block-heading\"><strong>MDSAP Audit Approach 2026: How It Differs from FDA Inspections Under QMSR<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">MDSAP audits and FDA inspections serve fundamentally different regulatory functions and must not be conflated.<\/p>\n\n<p class=\"wp-block-paragraph\">An MDSAP audit is conducted by an FDA-recognized Auditing Organization. It assesses conformity with harmonized quality management system requirements \u2014 ISO 13485 and the regulatory requirements of participating authorities including FDA. It is scheduled, structured, and conformity-focused. Participation remains voluntary.<\/p>\n\n<p class=\"wp-block-paragraph\">An FDA inspection is a statutory enforcement activity conducted directly by FDA investigators. Its objective is not certification \u2014 it is the evaluation of compliance with US legal requirements and the identification of potential violations, systemic weaknesses, or public health risks.<\/p>\n\n<figure class=\"wp-block-table\"><table><thead><tr><th><strong>MDSAP audit<\/strong><\/th><th><strong>FDA inspection (CP 7382.850)<\/strong><\/th><\/tr><\/thead><tbody><tr><td>Conformity-focused<\/td><td>Compliance-driven and enforceable<\/td><\/tr><tr><td>Scheduled and structured<\/td><td>Risk-based, for-cause, or routine<\/td><\/tr><tr><td>Bound by MDSAP task structure<\/td><td>Not limited by MDSAP scope or sampling<\/td><\/tr><tr><td>Outcome: certification report<\/td><td>Outcome: Form 483 \/ warning letter \/ no action<\/td><\/tr><tr><td>Internal records may not be reviewed<\/td><td>Internal audits, supplier audits, management reviews now in scope<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<p class=\"wp-block-paragraph\">Strong MDSAP performance may influence FDA surveillance planning. It does not eliminate the possibility of inspection, nor does it guarantee a favourable outcome when one occurs.<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>Common Assumptions That Increase Inspection Risk<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">Several structural misconceptions remain widespread. Under QMSR, these assumptions translate directly into inspection exposure.<\/p>\n\n<ul class=\"wp-block-list\">\n<li>\u00abMDSAP replaces FDA inspections.\u00bb It informs surveillance planning. It does not limit FDA&#8217;s statutory authority.<\/li>\n\n\n\n<li>\u00abIf the MDSAP auditor didn&#8217;t find it, FDA won&#8217;t pursue it.\u00bb FDA investigators are not constrained by MDSAP audit depth or task sequencing.<\/li>\n\n\n\n<li>\u00abISO 13485 certification ensures FDA compliance.\u00bb ISO 13485 is incorporated by reference into QMSR, but FDA-specific requirements \u2014 UDI, MDR, device listing, labeling controls \u2014 remain fully enforceable and are not covered by ISO 13485 alone.<\/li>\n\n\n\n<li>\u00abQMSR was a documentation update.\u00bb For ISO-certified manufacturers, many gaps are substantive \u2014 missing FDA-required record content, incomplete UDI integration, absent MDR linkage \u2014 not cosmetic.<\/li>\n<\/ul>\n\n<h2 class=\"wp-block-heading\"><strong>QMSR vs QSR vs ISO 13485: What Actually Changed<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">QMSR incorporates ISO 13485:2016 by reference into US law. That is a structural alignment, not a reduction in FDA enforcement authority. Obligations related to UDI, MDR, device listing, and labeling controls continue to apply in full.<\/p>\n\n<figure class=\"wp-block-table\"><table><thead><tr><th><strong>Element<\/strong><\/th><th><strong>Former QSR (21 CFR 820)<\/strong><\/th><th><strong>FDA QMSR (2026)<\/strong><\/th><th><strong>ISO 13485:2016<\/strong><\/th><\/tr><\/thead><tbody><tr><td>Legal status<\/td><td>US regulation<\/td><td>US regulation (ISO 13485 incorporated by reference)<\/td><td>International standard<\/td><\/tr><tr><td>Inspection model<\/td><td>QSIT subsystem checklists<\/td><td>CP 7382.850 \u2014 lifecycle, risk-based<\/td><td>Certification audit<\/td><\/tr><tr><td>Internal audit access<\/td><td>Limited under \u00a7820.180(c)<\/td><td>Internal audits and management reviews reviewable<\/td><td>Auditor access at certification<\/td><\/tr><tr><td>CAPA focus<\/td><td>Cumplimiento procedimental<\/td><td>Demonstrated effectiveness + root cause verification<\/td><td>Effectiveness required<\/td><\/tr><tr><td>FDA-specific requirements<\/td><td>Totalmente integrados<\/td><td>UDI, MDR, labeling still fully enforceable<\/td><td>No incluidos<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<blockquote class=\"wp-block-quote has-white-frost-background-color has-background has-medium-font-size is-layout-flow wp-block-quote-is-layout-flow\" style=\"border-left-color:var(--wp--preset--color--blue);border-left-width:6px\">\n<p class=\"wp-block-paragraph\"><strong>Takeaway: <\/strong>ISO 13485 alignment does not eliminate FDA-specific compliance obligations. A manufacturer can hold ISO 13485 certification and still have substantive QMSR gaps.<\/p>\n<\/blockquote>\n\n<h2 class=\"wp-block-heading\"><strong>FDA Compliance Program 7382.850: How Inspections Work<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">As of 2 February 2026, FDA retired QSIT and implemented Compliance Program 7382.850. Inspections are now organised around six integrated QMS areas and four Other Applicable FDA Requirements (OAFRs).<\/p>\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Six QMS areas<\/strong><\/td><td><strong>Four OAFRs<\/strong><\/td><\/tr><tr><td>Change Control<\/td><td>Unique Device Identification (UDI)<\/td><\/tr><tr><td>Design &amp; Development<\/td><td>Medical Device Reporting (MDR)<\/td><\/tr><tr><td>Management Oversight<\/td><td>Corrections &amp; Removals<\/td><\/tr><tr><td>Outsourcing &amp; Purchasing<\/td><td>Tracking<\/td><\/tr><tr><td>Production &amp; Service Provision<\/td><td><\/td><\/tr><tr><td>Measurement, Analysis &amp; Improvement<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n<p class=\"wp-block-paragraph\">Under this model, FDA evaluates how quality subsystems operate as an interconnected framework \u2014 not as isolated elements. Inspectors assess whether risk information, design decisions, post-market data, and management oversight are aligned throughout the product lifecycle.<\/p>\n\n<p class=\"wp-block-paragraph\"><strong>The Four Areas That Almost Always Reveal Gaps<\/strong><\/p>\n\n<p class=\"wp-block-paragraph\">Across QMSR gap assessments conducted on IVD and medical device manufacturers, four areas surface as gaps with consistent regularity \u2014 even in organisations that have maintained ISO 13485 certification for years.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>1. Complaint handling and servicing records<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">Many companies aligned with ISO 13485 underestimate the level of record detail FDA expects. Under QMSR, complaint and servicing records must include specific, enumerated data fields that ISO 13485 does not explicitly define. Records are often incomplete from an FDA perspective even when they satisfy the certification standard.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>2. UDI traceability and record integration<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">UDI compliance is not simply a matter of having a UDI assigned and registered in GUDID. QMSR requires the UDI to be consistently recorded across multiple record types: complaints, servicing records, and batch or device history records. That level of cross-system integration is frequently missing \u2014 particularly in manufacturers who completed UDI registration without reviewing how UDI flows through their quality records.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>3. Labeling and packaging controls<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">FDA maintains specific requirements for label content \u2014 including UDI, expiry dates, and handling instructions \u2014 and expects documented procedures designed to ensure accuracy and prevent mix-ups. These requirements are often handled informally or through processes that do not meet FDA&#8217;s explicit documentation expectations, even when the labels themselves are technically correct.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>4. Linkage between ISO processes and FDA regulatory requirements<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">This is the gap that most consistently surprises ISO-certified organisations. A company may have complaint handling aligned with ISO 13485 clause 8.2.2 and consider that requirement closed \u2014 but fail to explicitly connect that process to Medical Device Reporting obligations under 21 CFR Part 803. FDA does not treat ISO conformity as a substitute for regulatory linkage. Each process must demonstrably connect to the applicable FDA requirement in the documentation.<\/p>\n\n<blockquote class=\"wp-block-quote has-white-frost-background-color has-background has-medium-font-size is-layout-flow wp-block-quote-is-layout-flow\" style=\"border-left-color:var(--wp--preset--color--blue);border-left-width:6px\">\n<p class=\"wp-block-paragraph\"><em>\u00abCompanies often assume that having a robust ISO-aligned procedure is sufficient. What we find in practice is that the procedure exists \u2014 but there is no explicit documented connection between that procedure and the FDA-specific obligation it is meant to fulfil. That gap is invisible until an inspector asks for it.\u00bb<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Joana Martins, QA\/RA Specialist, MDx CRO<\/strong><\/p>\n<\/blockquote>\n\n<h2 class=\"wp-block-heading\"><strong>Why QMSR Gap Analysis Is More Complex for IVD and CDx Manufacturers<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">ISO 13485 and QMSR do not formally distinguish between device types. However, the nature of IVDs fundamentally changes which gaps are most consequential and how difficult they are to close.<\/p>\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img decoding=\"async\" width=\"1200\" height=\"675\" src=\"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSR-How-QMSR-compliance-and-FDA-inspection-readiness-interlock-for-medical-device-manufacturers-MDX-CRO.webp\" alt=\"Ilustraci&#xF3;n del proceso de inspecci&#xF3;n de la FDA que enfatiza los sistemas de gesti&#xF3;n de la calidad, las auditor&#xED;as basadas en riesgo y la preparaci&#xF3;n del fabricante en la industria MedTech.\" class=\"wp-image-9911\" style=\"width:760px;height:auto\" srcset=\"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSR-How-QMSR-compliance-and-FDA-inspection-readiness-interlock-for-medical-device-manufacturers-MDX-CRO.webp 1200w, https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSR-How-QMSR-compliance-and-FDA-inspection-readiness-interlock-for-medical-device-manufacturers-MDX-CRO-1067x600.webp 1067w, https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSR-How-QMSR-compliance-and-FDA-inspection-readiness-interlock-for-medical-device-manufacturers-MDX-CRO-768x432.webp 768w\" sizes=\"(max-width: 1200px) 100vw, 1200px\" \/><\/figure>\n\n<p class=\"wp-block-paragraph\">A QMSR gap analysis for an IVD manufacturer must extend beyond traditional quality system elements. It needs to integrate scientific validity, analytical performance, and clinical evidence into the assessment framework. Where a general medical device gap analysis evaluates whether a product is designed, manufactured, and controlled to ensure safety and functional performance, an IVD-focused analysis must additionally verify that the product generates clinically reliable results under real-world biological variability.<\/p>\n\n<figure class=\"wp-block-table\"><table><thead><tr><th><strong>Area<\/strong><\/th><th><strong>General medical device<\/strong><\/th><th><strong>IVD \/ CDx \u2014 additional complexity<\/strong><\/th><\/tr><\/thead><tbody><tr><td>Design controls<\/td><td>User needs, design inputs, outputs, V&amp;V<\/td><td>Intended use, specimen type, analyte definition, performance claims must link to analytical and clinical data<\/td><\/tr><tr><td>Risk management<\/td><td>Device failure modes<\/td><td>Must also cover false positive and false negative results, diagnostic decision risks, interfering substances, matrix effects<\/td><\/tr><tr><td>Production controls<\/td><td>Process validation, specifications<\/td><td>Lot-to-lot variability of biological materials must be validated against clinically relevant performance criteria<\/td><\/tr><tr><td>Post-market surveillance<\/td><td>Complaint handling, MDR<\/td><td>Must detect performance drift \u2014 shifts in sensitivity or specificity \u2014 not just product failures<\/td><\/tr><tr><td>Purchasing controls<\/td><td>Supplier qualification<\/td><td>Supplier variability can directly affect assay performance outcomes<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<blockquote class=\"wp-block-quote has-white-frost-background-color has-background has-medium-font-size is-layout-flow wp-block-quote-is-layout-flow\" style=\"border-left-color:var(--wp--preset--color--blue);border-left-width:6px\">\n<p class=\"wp-block-paragraph\"><em>\u00abFor IVDs, failures may not manifest as product defects \u2014 they manifest as clinically incorrect results. That is a more insidious form of non-compliance, and it means the risk management and design control documentation needs to work harder than it does for a general medical device.\u00bb<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Joana Martins, QA\/RA Specialist, MDx CRO<\/strong><\/p>\n<\/blockquote>\n\n<h2 class=\"wp-block-heading\"><strong>What FDA Is Finding in QMSR Inspections: Warning Letter Patterns<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">Recent warning letters issued by CDRH following QMSR inspections show a consistent pattern. Deficiencies are not isolated \u2014 they are interconnected, reflecting a failure to operate an effective integrated quality system rather than individual documentation gaps.<\/p>\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Finding category<\/strong><\/td><td><strong>Most common deficiency pattern<\/strong><\/td><\/tr><tr><td>CAPA<\/td><td>Procedures not defined or inadequate; failure to investigate root causes; CAPAs not verified for effectiveness<\/td><\/tr><tr><td>Complaint handling<\/td><td>Complaints not properly documented or evaluated; failure to assess whether complaints are reportable under MDR; no complaint trending or statistical analysis<\/td><\/tr><tr><td>Design controls<\/td><td>Lack of design verification and validation; poor documentation of design changes and their impact; no design and development plan or procedure<\/td><\/tr><tr><td>Supplier controls<\/td><td>Lack of defined quality requirements that suppliers must meet; no risk-based audit justification<\/td><\/tr><tr><td>Process validation<\/td><td>Manufacturing processes not validated; no revalidation after changes; validation protocols incomplete or not scientifically justified<\/td><\/tr><tr><td>Management responsibility<\/td><td>Management not actively involved in QMS; no effective management review with documented decisions and follow-up<br\/><\/td><\/tr><\/tbody><\/table><\/figure>\n\n<blockquote class=\"wp-block-quote has-white-frost-background-color has-background has-medium-font-size is-layout-flow wp-block-quote-is-layout-flow\" style=\"border-left-color:var(--wp--preset--color--blue);border-left-width:6px\">\n<p class=\"wp-block-paragraph\"><strong>Important: <\/strong>The FDA has clarified that if previous inspections were conducted under the QS Regulation (prior to 2 February 2026), any corrective actions proposed or implemented must now be pursued pursuant to QMSR requirements \u2014 not the former QSR standard.<\/p>\n<\/blockquote>\n\n<h2 class=\"wp-block-heading\"><strong>What FDA Inspectors Scrutinize Most<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">Based on regulatory inspection support experience, three documentation areas present heightened exposure under QMSR.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>1. Internal audits, supplier audits, and management review records<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">Under QMSR, FDA inspectors may review internal audit reports, supplier audit outcomes, and management review records. Investigators evaluate whether quality processes function effectively in practice \u2014 not merely whether procedures formally exist. Records must clearly demonstrate identified issues, root cause analysis, corrective actions, and documented closure. Incomplete or draft audit records increase inspection risk.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>2. Design controls and traceability (ISO 13485 clause 7.3)<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">Manufacturers must demonstrate full traceability across user needs, design inputs, design outputs, verification and validation, and residual risks. Traceability weaknesses frequently arise at the interfaces between risk management files, labeling claims, UDI triggers, and MDR criteria. For companion diagnostics, this alignment is especially critical because intended use, biomarker claims, and clinical evidence directly impact regulatory risk classification.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>3. CAPA and effectiveness verification<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">CAPA remains one of the most enforcement-sensitive areas under QMSR. The most common weakness is the absence of documented effectiveness verification following corrective actions. Closing a CAPA administratively \u2014 marking it complete without objective evidence that the root cause was eliminated \u2014 is insufficient. Investigators expect evidence demonstrating that actions prevented recurrence.<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>Inspection Risk Indicators<\/strong><\/h2>\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Risk area<\/strong><\/td><td><strong>Typical vulnerability<\/strong><\/td><\/tr><tr><td>CAPA<\/td><td>Problemas repetidos sin verificaci\u00f3n de eficacia documentada<\/td><\/tr><tr><td>Design controls<\/td><td>Trazabilidad incompleta entre el an\u00e1lisis de riesgos y las entradas de dise\u00f1o<\/td><\/tr><tr><td>Management review<\/td><td>Actas sin decisiones, m\u00e9tricas o acciones de seguimiento documentadas<\/td><\/tr><tr><td>Supplier oversight<\/td><td>No risk-based justification for audit scope; missing quality requirements for suppliers<\/td><\/tr><tr><td>Post-market surveillance<\/td><td>Tendencias de quejas no vinculadas a CAPA ni a actualizaciones de dise\u00f1o<\/td><\/tr><tr><td>UDI<\/td><td>Not consistently recorded across complaints, servicing records, and device history records<\/td><\/tr><tr><td>MDR linkage<\/td><td>Complaint handling procedures not explicitly connected to MDR reporting obligations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<h2 class=\"wp-block-heading\"><strong>How to Conduct a QMSR Gap Analysis: Process and Timeline<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">ISO 13485 certification does not automatically confirm FDA QMSR compliance. A structured gap analysis identifies the regulatory overlays and inspection exposure points that ISO conformity alone leaves unaddressed.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>What a QMSR gap analysis covers<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">A thorough assessment works through four stages:<\/p>\n\n<ol class=\"wp-block-list\">\n<li><strong>Clause mapping: <\/strong>Map ISO 13485 clauses to QMSR references. Confirm terminology alignment. Identify where the QMSR adds FDA-specific requirements beyond the ISO standard.<\/li>\n\n\n\n<li><strong>FDA-specific overlay identification: <\/strong>Verify explicit incorporation of UDI requirements across all applicable record types, MDR reporting triggers and their linkage to complaint handling, labeling obligations under 21 CFR Part 801, and device listing and registration controls.<\/li>\n\n\n\n<li><strong>Documentation exposure review: <\/strong>Assess internal audit completeness and whether records are inspection-ready, CAPA effectiveness evidence, management review decision traceability, and supplier risk classification and audit justification.<\/li>\n\n\n\n<li><strong>Risk prioritisation and remediation planning: <\/strong>Each gap is assessed for potential impact on quality, business continuity, and regulatory standing. Higher-risk gaps \u2014 those most likely to generate Form 483 observations or warning letters \u2014 are prioritised for remediation with assigned ownership and timelines.<\/li>\n<\/ol>\n\n<h3 class=\"wp-block-heading\"><strong>How long does it take?<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">A gap analysis typically takes 4\u20136 weeks, provided documentation is made available at the outset. Implementation of corrective actions depends on the number and severity of findings and on the responsiveness of the internal team.<\/p>\n\n<p class=\"wp-block-paragraph\">For manufacturers with both QMSR and ISO 13485 gaps, implementation may take 4\u20135 months. Where gaps are limited to QMSR-specific requirements in an otherwise ISO-aligned system, the timeline is typically shorter.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>The ISO 13485 certification gap \u2014 what &#8216;compliant&#8217; actually means<\/strong><\/h3>\n\n<p class=\"wp-block-paragraph\">A persistent scenario in QMSR readiness work: a manufacturer holds ISO 13485 certification, has documented procedures that appear robust, and believes ISO alignment is sufficient. Gaps emerge in missing FDA-required data fields in records, incomplete UDI implementation, and failure to link ISO processes to FDA regulatory requirements.<\/p>\n\n<p class=\"wp-block-paragraph\">They are structurally compliant with ISO but not fully aligned with FDA expectations. The distinction matters: an FDA inspector is not evaluating conformity to a certification standard. The inspector is evaluating compliance with US law and assessing whether the quality system actually functions as an integrated framework.<\/p>\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img decoding=\"async\" width=\"1200\" height=\"675\" src=\"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSR-strategies-for-modern-and-effective-compliance-MDx-CRO.webp\" alt=\"Gesti&#xF3;n de la calidad y proceso de inspecci&#xF3;n de productos sanitarios con formaci&#xF3;n de equipos, revisi&#xF3;n basada en datos y narrativas de inspecci&#xF3;n para el cumplimiento con la FDA.\" class=\"wp-image-9914\" style=\"aspect-ratio:1.7777994483296649;width:751px;height:auto\" srcset=\"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSR-strategies-for-modern-and-effective-compliance-MDx-CRO.webp 1200w, https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSR-strategies-for-modern-and-effective-compliance-MDx-CRO-1067x600.webp 1067w, https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSR-strategies-for-modern-and-effective-compliance-MDx-CRO-768x432.webp 768w\" sizes=\"(max-width: 1200px) 100vw, 1200px\" \/><\/figure>\n\n<div class=\"wp-block-group has-white-frost-color has-blue-background-color has-text-color has-background has-link-color wp-elements-1 has-global-padding is-layout-constrained wp-container-core-group-is-layout-4051523e wp-block-group-is-layout-constrained\" style=\"padding-top:var(--wp--preset--spacing--regular);padding-right:var(--wp--preset--spacing--regular);padding-bottom:var(--wp--preset--spacing--regular);padding-left:var(--wp--preset--spacing--regular)\">\n<p class=\"wp-block-paragraph\"><strong>Download<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>QMSR Gap Assessment Checklist for IVD and CDx Manufacturers \u2014 A structured reference document developed by the MDx CRO quality team. <\/strong><\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-blue-color has-white-frost-background-color has-text-color has-background has-link-color wp-element-button\">Download the FDA QMSR Gap Assessment Checklist<\/a><\/div>\n<\/div>\n<\/div>\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n<h2 id=\"mdsap-audit-approach\" class=\"wp-block-heading\"><strong>Practical Implications for Manufacturers<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\" id=\"mdsap-audit-approach\">Inspection scope may be data-driven. FDA may use pre-inspection data reviews to target areas of concern, increasing scrutiny where trends or inconsistencies are identified.<\/p>\n\n<p class=\"wp-block-paragraph\">FDA inspectors are evaluating how quality processes work together in practice \u2014 not whether each subsystem satisfies a checklist in isolation.<\/p>\n\n<p class=\"wp-block-paragraph\">Previously internal records are now fair game. Internal audit reports, supplier audit outcomes, and management review records may be reviewed. These documents must reflect issues identified, decisions made, and actions taken.<\/p>\n\n<p class=\"wp-block-paragraph\">Risk management must be continuous and demonstrable. FDA expects risk to be actively monitored and linked to CAPA, design changes, supplier controls, and post-market surveillance \u2014 not treated as a static exercise.<\/p>\n\n<p class=\"wp-block-paragraph\">Post-market data is a primary inspection focus. Complaint trends, MDR, recalls, UDI, and tracking data are increasingly used to assess whether the quality system is effective and responsive.<\/p>\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<h2 class=\"wp-block-heading\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">C\u00f3mo MDx apoya la preparaci\u00f3n para la FDA QMSR: visi\u00f3n experta<\/mark><\/h2>\n\n<p class=\"wp-block-paragraph\">La transici\u00f3n de QSR a FDA QMSR requiere m\u00e1s que actualizar la terminolog\u00eda. Exige alineaci\u00f3n estructural y preparaci\u00f3n orientada a inspecciones. <\/p>\n\n<p class=\"wp-block-paragraph\">Bas\u00e1ndose en la experiencia de campo apoyando a fabricantes en la preparaci\u00f3n para inspecciones y en proyectos de alineaci\u00f3n regulatoria, Joana Martins, especialista en QA\/RA en MDx, destaca que las vulnerabilidades m\u00e1s frecuentes no provienen de procedimientos ausentes, sino de una eficacia del sistema insuficientemente demostrada.<\/p>\n\n<p class=\"wp-block-paragraph\">Seg\u00fan la experiencia de Joana en preparaci\u00f3n para inspecciones, las organizaciones suelen subestimar <strong>tres puntos de exposici\u00f3n<\/strong> durante la preparaci\u00f3n para inspecciones de la FDA:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>La <strong>profundidad de la revisi\u00f3n<\/strong> de documentaci\u00f3n ahora permitida bajo la QMSR<\/li>\n\n\n\n<li>La necesidad de <strong>trazabilidad<\/strong> entre la gesti\u00f3n de riesgos, los controles de dise\u00f1o y los datos poscomercializaci\u00f3n<\/li>\n\n\n\n<li>La importancia de la verificaci\u00f3n <strong>documentada de la eficacia<\/strong> dentro de los sistemas CAPA<\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\">Para abordar estos puntos de exposici\u00f3n, MDx apoya a los fabricantes de productos sanitarios mediante:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Evaluaciones independientes de preparaci\u00f3n alineadas con QMSR, centradas en la exposici\u00f3n durante inspecciones<\/li>\n\n\n\n<li>An\u00e1lisis estructurados de brechas de la QMSR que incorporan a\u00f1adidos regulatorios espec\u00edficos de la FDA<\/li>\n\n\n\n<li>Inspecciones simuladas de la FDA alineadas con el Compliance Program 7382.850<\/li>\n\n\n\n<li>Apoyo estrat\u00e9gico para empresas que desarrollan diagn\u00f3sticos complementarios de la FDA, donde la trazabilidad del dise\u00f1o, los controles de etiquetado y la integraci\u00f3n de datos del ciclo de vida requieren una coherencia regulatoria reforzada<\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\">En lugar de abordar la FDA QMSR como una actualizaci\u00f3n documental, MDx trabaja con las organizaciones para garantizar que sus sistemas de calidad demuestren integridad operativa, toma de decisiones basada en riesgo y resiliencia ante inspecciones.<\/p>\n\n<p class=\"wp-block-paragraph\">Las organizaciones que se preparan para una inspecci\u00f3n de la FDA o eval\u00faan su alineaci\u00f3n con la QMSR pueden beneficiarse de una evaluaci\u00f3n temprana y estructurada. La evaluaci\u00f3n proactiva reduce los plazos de remediaci\u00f3n, minimiza la interrupci\u00f3n por inspecciones y refuerza la confianza regulatoria. <\/p>\n\n<div style=\"height:79px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<h2 class=\"wp-block-heading\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">Preguntas frecuentes sobre la FDA QMSR, MDSAP y las inspecciones<\/mark><\/strong><\/h2>\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1771601175364\"><strong class=\"schema-faq-question\"><strong>\u00bfCu\u00e1l es la principal diferencia entre QSR y QMSR?<\/strong><\/strong> <p class=\"schema-faq-answer\">La principal diferencia es la alineaci\u00f3n estructural. Bajo QSR, los requisitos de la FDA estaban redactados directamente en 21 CFR Part 820. Bajo QMSR, la FDA incorpora <strong>ISO 13485:2016 por referencia<\/strong> a la legislaci\u00f3n estadounidense, manteniendo vigentes las obligaciones espec\u00edficas de la FDA. En resumen, la QMSR armoniza la estructura con la ISO 13485. Sin embargo, no reduce la autoridad de aplicaci\u00f3n de la FDA ni elimina requisitos espec\u00edficos de EE. UU. como MDR, UDI o el registro\/listado de dispositivos.    <\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1771601200977\"><strong class=\"schema-faq-question\"><strong>\u00bfLa certificaci\u00f3n ISO 13485 garantiza el cumplimiento con la FDA bajo la QMSR?<\/strong><\/strong> <p class=\"schema-faq-answer\">No. Aunque la ISO 13485 constituye la base de la QMSR, los requisitos legales espec\u00edficos de la FDA siguen aplic\u00e1ndose. Los fabricantes deben cumplir con MDR, correcciones y retiradas, UDI y otras obligaciones de EE. UU. Seg\u00fan la experiencia regulatoria, las empresas suelen asumir que la certificaci\u00f3n ISO cierra todas las brechas. En la pr\u00e1ctica, es necesaria una evaluaci\u00f3n de brechas de la QMSR espec\u00edfica para confirmar la alineaci\u00f3n completa con la FDA.    <\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1771601216193\"><strong class=\"schema-faq-question\"><strong>\u00bfQu\u00e9 sustituy\u00f3 a QSIT en las inspecciones de la FDA?<\/strong><\/strong> <p class=\"schema-faq-answer\">La FDA sustituy\u00f3 QSIT por el <strong>Compliance Program 7382.850<\/strong>, con efecto el 2 de febrero de 2026. Este nuevo programa alinea las inspecciones con el marco de la QMSR. En lugar de listas de verificaci\u00f3n por subsistemas, la FDA ahora organiza las inspecciones en torno a seis \u00e1reas del QMS y cuatro Other Applicable FDA Requirements (OAFR). Como resultado, las inspecciones siguen un enfoque m\u00e1s integrado, basado en riesgo y centrado en el ciclo de vida.   <\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1771601238026\"><strong class=\"schema-faq-question\"><strong>\u00bfPuede la FDA inspeccionar informes de auditor\u00eda interna bajo la QMSR?<\/strong><\/strong> <p class=\"schema-faq-answer\">S\u00ed. Bajo la QMSR, los investigadores de la FDA pueden revisar informes de auditor\u00eda interna, auditor\u00edas de proveedores y registros de revisi\u00f3n por la direcci\u00f3n.<br\/>En la pr\u00e1ctica, los inspectores ahora verifican si las incidencias se identificaron, documentaron y cerraron de forma efectiva. Ya no se centran solo en si existen procedimientos; eval\u00faan si el sistema funciona seg\u00fan lo previsto.<br\/>Las acciones de auditor\u00eda incompletas o no verificadas pueden aumentar el riesgo de inspecci\u00f3n. <\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1771601252435\"><strong class=\"schema-faq-question\"><strong>\u00bfQu\u00e9 registros est\u00e1n recibiendo ahora mayor escrutinio durante las inspecciones de la FDA?<\/strong><\/strong> <p class=\"schema-faq-answer\">La FDA ahora pone mayor escrutinio en:<br\/>\u2013 Informes de auditor\u00eda interna y de proveedores<br\/>\u2013 Documentaci\u00f3n de revisi\u00f3n por la direcci\u00f3n<br\/>\u2013 Registros de trazabilidad de controles de dise\u00f1o<br\/>\u2013 Procedimientos CAPA y comprobaciones de eficacia<br\/>Seg\u00fan la experiencia en inspecciones, la verificaci\u00f3n de eficacia de CAPA es un punto d\u00e9bil frecuente. Las empresas suelen implementar acciones correctivas, pero no documentan evidencia objetiva de que la acci\u00f3n resolvi\u00f3 la causa ra\u00edz.<br\/>Bajo la QMSR, la eficacia importa tanto como la documentaci\u00f3n. <\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1771601274703\"><strong class=\"schema-faq-question\"><strong>\u00bfPor qu\u00e9 las empresas que superaron MDSAP siguen recibiendo observaciones FDA 483?<\/strong><\/strong> <p class=\"schema-faq-answer\">Porque MDSAP y las inspecciones de la FDA tienen finalidades distintas. MDSAP eval\u00faa la conformidad. Las inspecciones de la FDA eval\u00faan el cumplimiento legal y el riesgo para la salud p\u00fablica. Los investigadores de la FDA no est\u00e1n sujetos a los m\u00e9todos de muestreo ni al alcance de auditor\u00eda de MDSAP. Si los inspectores identifican CAPA ineficaz, trazabilidad d\u00e9bil o brechas entre los procedimientos y la pr\u00e1ctica real, pueden emitir observaciones en el Formulario 483, incluso tras una auditor\u00eda MDSAP satisfactoria.    <\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1771601293741\"><strong class=\"schema-faq-question\"><strong>\u00bfC\u00f3mo deber\u00edan prepararse los fabricantes para las inspecciones de la FDA bajo la QMSR?<\/strong><\/strong> <p class=\"schema-faq-answer\">Empiece pronto. La preparaci\u00f3n suele llevar m\u00e1s tiempo del esperado. Despu\u00e9s, realice una evaluaci\u00f3n estructurada de brechas de la QMSR. El cumplimiento con ISO 13485 por s\u00ed solo no confirma la alineaci\u00f3n completa con la FDA. Por \u00faltimo, forme a los equipos en el Compliance Program 7382.850. Las entrevistas simuladas y las simulaciones de inspecci\u00f3n ayudan a identificar debilidades. Incluso una remediaci\u00f3n documentada en curso demuestra control del sistema y reduce el riesgo de inspecci\u00f3n.      <\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1772817091955\"><strong class=\"schema-faq-question\"><strong>\u00bfCu\u00e1ndo comienza la aplicaci\u00f3n de la FDA QMSR?<\/strong><\/strong> <p class=\"schema-faq-answer\">La aplicaci\u00f3n de la FDA QMSR comenz\u00f3 el 2 de febrero de 2026, cuando la nueva Quality Management System Regulation sustituy\u00f3 oficialmente a la anterior Quality System Regulation (21 CFR Part 820). A partir de esa fecha, las inspecciones de la FDA operan bajo el Compliance Program 7382.850. <\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1772817100964\"><strong class=\"schema-faq-question\"><strong>\u00bfCu\u00e1les son los requisitos de armonizaci\u00f3n entre la FDA QMSR y la ISO 13485 para 2026?<\/strong> <\/strong> <p class=\"schema-faq-answer\">Bajo la QMSR de 2026, la ISO 13485:2016 se incorpora por referencia a la legislaci\u00f3n estadounidense. Esto significa que los fabricantes deben cumplir los requisitos de la ISO 13485 como parte del cumplimiento con la FDA. Sin embargo, la armonizaci\u00f3n no es una equivalencia completa: las obligaciones espec\u00edficas de la FDA, como UDI, notificaci\u00f3n MDR, registro\/listado de dispositivos y controles de etiquetado, siguen siendo plenamente exigibles y no est\u00e1n cubiertas \u00fanicamente por la ISO 13485. Consulte la tabla comparativa QSR vs QMSR vs ISO 13485 anterior para un desglose detallado.   <\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Gu\u00eda pr\u00e1ctica para fabricantes de productos sanitarios que explica los cambios de la FDA QMSR, la alineaci\u00f3n con MDSAP, las inspecciones y los pasos clave de preparaci\u00f3n para el cumplimiento.<\/p>\n","protected":false},"author":12,"featured_media":10086,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[231,216],"tags":[771,233,548],"resources-sector":[178,180,179],"class_list":["post-10285","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualizaciones-normativas","category-blog-2","tag-21-cfr-parte-820","tag-cumplimiento-normativo","tag-fda-qmsr","resources-sector-ivds","resources-sector-medical-devices","resources-sector-precision-medicine-cdx"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA QMSR 2026: qu\u00e9 cambia para las inspecciones en 2026<\/title>\n<meta name=\"description\" content=\"FDA QMSR explicado: c\u00f3mo la normativa de 2026 redefine las auditor\u00edas MDSAP, las inspecciones de la FDA, el escrutinio de CAPA y la preparaci\u00f3n para inspecciones en MDx.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA QMSR 2026: qu\u00e9 cambia para las inspecciones en 2026\" \/>\n<meta property=\"og:description\" content=\"FDA QMSR explicado: c\u00f3mo la normativa de 2026 redefine las auditor\u00edas MDSAP, las inspecciones de la FDA, el escrutinio de CAPA y la preparaci\u00f3n para inspecciones en MDx.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/\" \/>\n<meta property=\"og:site_name\" content=\"MDx CRO\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-20T17:03:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-23T11:57:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSRHow-the-2026-Regulation-Shift-Transforms-MDSAP-Audits-and-FDA-Compliance-Inspections-MDx-CRO.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Joana Martins\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joana Martins\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"18 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/\"},\"author\":{\"name\":\"Joana Martins\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#\\\/schema\\\/person\\\/c5cc5498991224b04475b4c44f62746e\"},\"headline\":\"FDA QMSR: c\u00f3mo el cambio normativo de 2026 transforma las auditor\u00edas MDSAP y las inspecciones de cumplimiento de la FDA\",\"datePublished\":\"2026-02-20T17:03:44+00:00\",\"dateModified\":\"2026-07-23T11:57:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/\"},\"wordCount\":3648,\"publisher\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/FDA-QMSRHow-the-2026-Regulation-Shift-Transforms-MDSAP-Audits-and-FDA-Compliance-Inspections-MDx-CRO.webp\",\"keywords\":[\"21 CFR Parte 820\",\"Cumplimiento normativo\",\"FDA QMSR\"],\"articleSection\":[\"Actualizaciones normativas\",\"Blog\"],\"inLanguage\":\"es\"},{\"@type\":[\"WebPage\",\"FAQPage\"],\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/\",\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/\",\"name\":\"FDA QMSR 2026: qu\u00e9 cambia para las inspecciones en 2026\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/FDA-QMSRHow-the-2026-Regulation-Shift-Transforms-MDSAP-Audits-and-FDA-Compliance-Inspections-MDx-CRO.webp\",\"datePublished\":\"2026-02-20T17:03:44+00:00\",\"dateModified\":\"2026-07-23T11:57:04+00:00\",\"description\":\"FDA QMSR explicado: c\u00f3mo la normativa de 2026 redefine las auditor\u00edas MDSAP, las inspecciones de la FDA, el escrutinio de CAPA y la preparaci\u00f3n para inspecciones en MDx.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#breadcrumb\"},\"mainEntity\":[{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601175364\"},{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601200977\"},{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601216193\"},{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601238026\"},{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601252435\"},{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601274703\"},{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601293741\"},{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1772817091955\"},{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1772817100964\"}],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/FDA-QMSRHow-the-2026-Regulation-Shift-Transforms-MDSAP-Audits-and-FDA-Compliance-Inspections-MDx-CRO.webp\",\"contentUrl\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/FDA-QMSRHow-the-2026-Regulation-Shift-Transforms-MDSAP-Audits-and-FDA-Compliance-Inspections-MDx-CRO.webp\",\"width\":1200,\"height\":630,\"caption\":\"Un profesional sanitario calibra un sofisticado producto sanitario, destacando el papel de MDX en el avance de soluciones MedTech para mejorar la atenci\u00f3n al paciente y el cumplimiento regulatorio.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA QMSR: c\u00f3mo el cambio normativo de 2026 transforma las auditor\u00edas MDSAP y las inspecciones de cumplimiento de la FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/\",\"name\":\"MDx CRO\",\"description\":\"Investigaci\u00f3n cl\u00ednica, normativa y control de calidad en tecnolog\u00eda m\u00e9dica y diagn\u00f3stico in vitro\",\"publisher\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#organization\"},\"alternateName\":\"MDx\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#organization\",\"name\":\"CRO de MDx\",\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/MDX.svg\",\"contentUrl\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/MDX.svg\",\"width\":352,\"height\":114,\"caption\":\"CRO de MDx\"},\"image\":{\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/medtech-ivd-cro\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/#\\\/schema\\\/person\\\/c5cc5498991224b04475b4c44f62746e\",\"name\":\"Joana Martins\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Joana-Martins-Team-MDxCRO.png-96x96.webp\",\"url\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Joana-Martins-Team-MDxCRO.png-96x96.webp\",\"contentUrl\":\"https:\\\/\\\/mdxcro.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Joana-Martins-Team-MDxCRO.png-96x96.webp\",\"caption\":\"Joana Martins\"},\"description\":\"Joana Martins is a Quality Assurance and Regulatory Affairs Specialist with over 10 years of experience in medical devices, quality management, and product development. She specialises in ISO 13485 quality management systems, FDA regulatory requirements, technical documentation, risk management, and post-market surveillance activities. Throughout her career in both industry and research, Joana has supported the development and regulatory compliance of innovative medical devices, helping manufacturers bring safe, compliant products to market.\",\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/joanamartinsmeddev\\\/\"],\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/autor\\\/joana-martins\\\/\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601175364\",\"position\":1,\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601175364\",\"name\":\"\u00bfCu\u00e1l es la principal diferencia entre QSR y QMSR?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"La principal diferencia es la alineaci\u00f3n estructural. Bajo QSR, los requisitos de la FDA estaban redactados directamente en 21 CFR Part 820. Bajo QMSR, la FDA incorpora <strong>ISO 13485:2016 por referencia<\\\/strong> a la legislaci\u00f3n estadounidense, manteniendo vigentes las obligaciones espec\u00edficas de la FDA. En resumen, la QMSR armoniza la estructura con la ISO 13485. Sin embargo, no reduce la autoridad de aplicaci\u00f3n de la FDA ni elimina requisitos espec\u00edficos de EE. UU. como MDR, UDI o el registro\\\/listado de dispositivos.    \",\"inLanguage\":\"es\"},\"inLanguage\":\"es\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601200977\",\"position\":2,\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601200977\",\"name\":\"\u00bfLa certificaci\u00f3n ISO 13485 garantiza el cumplimiento con la FDA bajo la QMSR?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. Aunque la ISO 13485 constituye la base de la QMSR, los requisitos legales espec\u00edficos de la FDA siguen aplic\u00e1ndose. Los fabricantes deben cumplir con MDR, correcciones y retiradas, UDI y otras obligaciones de EE. UU. Seg\u00fan la experiencia regulatoria, las empresas suelen asumir que la certificaci\u00f3n ISO cierra todas las brechas. En la pr\u00e1ctica, es necesaria una evaluaci\u00f3n de brechas de la QMSR espec\u00edfica para confirmar la alineaci\u00f3n completa con la FDA.    \",\"inLanguage\":\"es\"},\"inLanguage\":\"es\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601216193\",\"position\":3,\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601216193\",\"name\":\"\u00bfQu\u00e9 sustituy\u00f3 a QSIT en las inspecciones de la FDA?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"La FDA sustituy\u00f3 QSIT por el <strong>Compliance Program 7382.850<\\\/strong>, con efecto el 2 de febrero de 2026. Este nuevo programa alinea las inspecciones con el marco de la QMSR. En lugar de listas de verificaci\u00f3n por subsistemas, la FDA ahora organiza las inspecciones en torno a seis \u00e1reas del QMS y cuatro Other Applicable FDA Requirements (OAFR). Como resultado, las inspecciones siguen un enfoque m\u00e1s integrado, basado en riesgo y centrado en el ciclo de vida.   \",\"inLanguage\":\"es\"},\"inLanguage\":\"es\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601238026\",\"position\":4,\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601238026\",\"name\":\"\u00bfPuede la FDA inspeccionar informes de auditor\u00eda interna bajo la QMSR?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"S\u00ed. Bajo la QMSR, los investigadores de la FDA pueden revisar informes de auditor\u00eda interna, auditor\u00edas de proveedores y registros de revisi\u00f3n por la direcci\u00f3n.<br>En la pr\u00e1ctica, los inspectores ahora verifican si las incidencias se identificaron, documentaron y cerraron de forma efectiva. Ya no se centran solo en si existen procedimientos; eval\u00faan si el sistema funciona seg\u00fan lo previsto.<br>Las acciones de auditor\u00eda incompletas o no verificadas pueden aumentar el riesgo de inspecci\u00f3n. \",\"inLanguage\":\"es\"},\"inLanguage\":\"es\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601252435\",\"position\":5,\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601252435\",\"name\":\"\u00bfQu\u00e9 registros est\u00e1n recibiendo ahora mayor escrutinio durante las inspecciones de la FDA?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"La FDA ahora pone mayor escrutinio en:<br>- Informes de auditor\u00eda interna y de proveedores<br>- Documentaci\u00f3n de revisi\u00f3n por la direcci\u00f3n<br>- Registros de trazabilidad de controles de dise\u00f1o<br>- Procedimientos CAPA y comprobaciones de eficacia<br>Seg\u00fan la experiencia en inspecciones, la verificaci\u00f3n de eficacia de CAPA es un punto d\u00e9bil frecuente. Las empresas suelen implementar acciones correctivas, pero no documentan evidencia objetiva de que la acci\u00f3n resolvi\u00f3 la causa ra\u00edz.<br>Bajo la QMSR, la eficacia importa tanto como la documentaci\u00f3n. \",\"inLanguage\":\"es\"},\"inLanguage\":\"es\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601274703\",\"position\":6,\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601274703\",\"name\":\"\u00bfPor qu\u00e9 las empresas que superaron MDSAP siguen recibiendo observaciones FDA 483?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Porque MDSAP y las inspecciones de la FDA tienen finalidades distintas. MDSAP eval\u00faa la conformidad. Las inspecciones de la FDA eval\u00faan el cumplimiento legal y el riesgo para la salud p\u00fablica. Los investigadores de la FDA no est\u00e1n sujetos a los m\u00e9todos de muestreo ni al alcance de auditor\u00eda de MDSAP. Si los inspectores identifican CAPA ineficaz, trazabilidad d\u00e9bil o brechas entre los procedimientos y la pr\u00e1ctica real, pueden emitir observaciones en el Formulario 483, incluso tras una auditor\u00eda MDSAP satisfactoria.    \",\"inLanguage\":\"es\"},\"inLanguage\":\"es\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601293741\",\"position\":7,\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1771601293741\",\"name\":\"\u00bfC\u00f3mo deber\u00edan prepararse los fabricantes para las inspecciones de la FDA bajo la QMSR?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Empiece pronto. La preparaci\u00f3n suele llevar m\u00e1s tiempo del esperado. Despu\u00e9s, realice una evaluaci\u00f3n estructurada de brechas de la QMSR. El cumplimiento con ISO 13485 por s\u00ed solo no confirma la alineaci\u00f3n completa con la FDA. Por \u00faltimo, forme a los equipos en el Compliance Program 7382.850. Las entrevistas simuladas y las simulaciones de inspecci\u00f3n ayudan a identificar debilidades. Incluso una remediaci\u00f3n documentada en curso demuestra control del sistema y reduce el riesgo de inspecci\u00f3n.      \",\"inLanguage\":\"es\"},\"inLanguage\":\"es\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1772817091955\",\"position\":8,\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1772817091955\",\"name\":\"\u00bfCu\u00e1ndo comienza la aplicaci\u00f3n de la FDA QMSR?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"La aplicaci\u00f3n de la FDA QMSR comenz\u00f3 el 2 de febrero de 2026, cuando la nueva Quality Management System Regulation sustituy\u00f3 oficialmente a la anterior Quality System Regulation (21 CFR Part 820). A partir de esa fecha, las inspecciones de la FDA operan bajo el Compliance Program 7382.850. \",\"inLanguage\":\"es\"},\"inLanguage\":\"es\"},{\"@type\":\"Question\",\"@id\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1772817100964\",\"position\":9,\"url\":\"https:\\\/\\\/mdxcro.com\\\/es\\\/fda-qmsr-regulacion-sistema-gestion-calidad\\\/#faq-question-1772817100964\",\"name\":\"\u00bfCu\u00e1les son los requisitos de armonizaci\u00f3n entre la FDA QMSR y la ISO 13485 para 2026?\",\"answerCount\":1,\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Bajo la QMSR de 2026, la ISO 13485:2016 se incorpora por referencia a la legislaci\u00f3n estadounidense. Esto significa que los fabricantes deben cumplir los requisitos de la ISO 13485 como parte del cumplimiento con la FDA. Sin embargo, la armonizaci\u00f3n no es una equivalencia completa: las obligaciones espec\u00edficas de la FDA, como UDI, notificaci\u00f3n MDR, registro\\\/listado de dispositivos y controles de etiquetado, siguen siendo plenamente exigibles y no est\u00e1n cubiertas \u00fanicamente por la ISO 13485. Consulte la tabla comparativa QSR vs QMSR vs ISO 13485 anterior para un desglose detallado.   \",\"inLanguage\":\"es\"},\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA QMSR 2026: qu\u00e9 cambia para las inspecciones en 2026","description":"FDA QMSR explicado: c\u00f3mo la normativa de 2026 redefine las auditor\u00edas MDSAP, las inspecciones de la FDA, el escrutinio de CAPA y la preparaci\u00f3n para inspecciones en MDx.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/","og_locale":"es_ES","og_type":"article","og_title":"FDA QMSR 2026: qu\u00e9 cambia para las inspecciones en 2026","og_description":"FDA QMSR explicado: c\u00f3mo la normativa de 2026 redefine las auditor\u00edas MDSAP, las inspecciones de la FDA, el escrutinio de CAPA y la preparaci\u00f3n para inspecciones en MDx.","og_url":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/","og_site_name":"MDx CRO","article_published_time":"2026-02-20T17:03:44+00:00","article_modified_time":"2026-07-23T11:57:04+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSRHow-the-2026-Regulation-Shift-Transforms-MDSAP-Audits-and-FDA-Compliance-Inspections-MDx-CRO.webp","type":"image\/webp"}],"author":"Joana Martins","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Joana Martins","Tiempo de lectura":"18 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#article","isPartOf":{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/"},"author":{"name":"Joana Martins","@id":"https:\/\/mdxcro.com\/es\/#\/schema\/person\/c5cc5498991224b04475b4c44f62746e"},"headline":"FDA QMSR: c\u00f3mo el cambio normativo de 2026 transforma las auditor\u00edas MDSAP y las inspecciones de cumplimiento de la FDA","datePublished":"2026-02-20T17:03:44+00:00","dateModified":"2026-07-23T11:57:04+00:00","mainEntityOfPage":{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/"},"wordCount":3648,"publisher":{"@id":"https:\/\/mdxcro.com\/es\/#organization"},"image":{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#primaryimage"},"thumbnailUrl":"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSRHow-the-2026-Regulation-Shift-Transforms-MDSAP-Audits-and-FDA-Compliance-Inspections-MDx-CRO.webp","keywords":["21 CFR Parte 820","Cumplimiento normativo","FDA QMSR"],"articleSection":["Actualizaciones normativas","Blog"],"inLanguage":"es"},{"@type":["WebPage","FAQPage"],"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/","url":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/","name":"FDA QMSR 2026: qu\u00e9 cambia para las inspecciones en 2026","isPartOf":{"@id":"https:\/\/mdxcro.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#primaryimage"},"image":{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#primaryimage"},"thumbnailUrl":"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSRHow-the-2026-Regulation-Shift-Transforms-MDSAP-Audits-and-FDA-Compliance-Inspections-MDx-CRO.webp","datePublished":"2026-02-20T17:03:44+00:00","dateModified":"2026-07-23T11:57:04+00:00","description":"FDA QMSR explicado: c\u00f3mo la normativa de 2026 redefine las auditor\u00edas MDSAP, las inspecciones de la FDA, el escrutinio de CAPA y la preparaci\u00f3n para inspecciones en MDx.","breadcrumb":{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#breadcrumb"},"mainEntity":[{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601175364"},{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601200977"},{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601216193"},{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601238026"},{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601252435"},{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601274703"},{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601293741"},{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1772817091955"},{"@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1772817100964"}],"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#primaryimage","url":"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSRHow-the-2026-Regulation-Shift-Transforms-MDSAP-Audits-and-FDA-Compliance-Inspections-MDx-CRO.webp","contentUrl":"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/02\/FDA-QMSRHow-the-2026-Regulation-Shift-Transforms-MDSAP-Audits-and-FDA-Compliance-Inspections-MDx-CRO.webp","width":1200,"height":630,"caption":"Un profesional sanitario calibra un sofisticado producto sanitario, destacando el papel de MDX en el avance de soluciones MedTech para mejorar la atenci\u00f3n al paciente y el cumplimiento regulatorio."},{"@type":"BreadcrumbList","@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mdxcro.com\/es\/"},{"@type":"ListItem","position":2,"name":"FDA QMSR: c\u00f3mo el cambio normativo de 2026 transforma las auditor\u00edas MDSAP y las inspecciones de cumplimiento de la FDA"}]},{"@type":"WebSite","@id":"https:\/\/mdxcro.com\/es\/#website","url":"https:\/\/mdxcro.com\/es\/","name":"MDx CRO","description":"Investigaci\u00f3n cl\u00ednica, normativa y control de calidad en tecnolog\u00eda m\u00e9dica y diagn\u00f3stico in vitro","publisher":{"@id":"https:\/\/mdxcro.com\/es\/#organization"},"alternateName":"MDx","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mdxcro.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/mdxcro.com\/es\/#organization","name":"CRO de MDx","url":"https:\/\/mdxcro.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/mdxcro.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/mdxcro.com\/wp-content\/uploads\/2025\/07\/MDX.svg","contentUrl":"https:\/\/mdxcro.com\/wp-content\/uploads\/2025\/07\/MDX.svg","width":352,"height":114,"caption":"CRO de MDx"},"image":{"@id":"https:\/\/mdxcro.com\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/medtech-ivd-cro"]},{"@type":"Person","@id":"https:\/\/mdxcro.com\/es\/#\/schema\/person\/c5cc5498991224b04475b4c44f62746e","name":"Joana Martins","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/01\/Joana-Martins-Team-MDxCRO.png-96x96.webp","url":"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/01\/Joana-Martins-Team-MDxCRO.png-96x96.webp","contentUrl":"https:\/\/mdxcro.com\/wp-content\/uploads\/2026\/01\/Joana-Martins-Team-MDxCRO.png-96x96.webp","caption":"Joana Martins"},"description":"Joana Martins is a Quality Assurance and Regulatory Affairs Specialist with over 10 years of experience in medical devices, quality management, and product development. She specialises in ISO 13485 quality management systems, FDA regulatory requirements, technical documentation, risk management, and post-market surveillance activities. Throughout her career in both industry and research, Joana has supported the development and regulatory compliance of innovative medical devices, helping manufacturers bring safe, compliant products to market.","sameAs":["https:\/\/www.linkedin.com\/in\/joanamartinsmeddev\/"],"url":"https:\/\/mdxcro.com\/es\/autor\/joana-martins\/"},{"@type":"Question","@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601175364","position":1,"url":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601175364","name":"\u00bfCu\u00e1l es la principal diferencia entre QSR y QMSR?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"La principal diferencia es la alineaci\u00f3n estructural. Bajo QSR, los requisitos de la FDA estaban redactados directamente en 21 CFR Part 820. Bajo QMSR, la FDA incorpora <strong>ISO 13485:2016 por referencia<\/strong> a la legislaci\u00f3n estadounidense, manteniendo vigentes las obligaciones espec\u00edficas de la FDA. En resumen, la QMSR armoniza la estructura con la ISO 13485. Sin embargo, no reduce la autoridad de aplicaci\u00f3n de la FDA ni elimina requisitos espec\u00edficos de EE. UU. como MDR, UDI o el registro\/listado de dispositivos.    ","inLanguage":"es"},"inLanguage":"es"},{"@type":"Question","@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601200977","position":2,"url":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601200977","name":"\u00bfLa certificaci\u00f3n ISO 13485 garantiza el cumplimiento con la FDA bajo la QMSR?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"No. Aunque la ISO 13485 constituye la base de la QMSR, los requisitos legales espec\u00edficos de la FDA siguen aplic\u00e1ndose. Los fabricantes deben cumplir con MDR, correcciones y retiradas, UDI y otras obligaciones de EE. UU. Seg\u00fan la experiencia regulatoria, las empresas suelen asumir que la certificaci\u00f3n ISO cierra todas las brechas. En la pr\u00e1ctica, es necesaria una evaluaci\u00f3n de brechas de la QMSR espec\u00edfica para confirmar la alineaci\u00f3n completa con la FDA.    ","inLanguage":"es"},"inLanguage":"es"},{"@type":"Question","@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601216193","position":3,"url":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601216193","name":"\u00bfQu\u00e9 sustituy\u00f3 a QSIT en las inspecciones de la FDA?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"La FDA sustituy\u00f3 QSIT por el <strong>Compliance Program 7382.850<\/strong>, con efecto el 2 de febrero de 2026. Este nuevo programa alinea las inspecciones con el marco de la QMSR. En lugar de listas de verificaci\u00f3n por subsistemas, la FDA ahora organiza las inspecciones en torno a seis \u00e1reas del QMS y cuatro Other Applicable FDA Requirements (OAFR). Como resultado, las inspecciones siguen un enfoque m\u00e1s integrado, basado en riesgo y centrado en el ciclo de vida.   ","inLanguage":"es"},"inLanguage":"es"},{"@type":"Question","@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601238026","position":4,"url":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601238026","name":"\u00bfPuede la FDA inspeccionar informes de auditor\u00eda interna bajo la QMSR?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"S\u00ed. Bajo la QMSR, los investigadores de la FDA pueden revisar informes de auditor\u00eda interna, auditor\u00edas de proveedores y registros de revisi\u00f3n por la direcci\u00f3n.<br>En la pr\u00e1ctica, los inspectores ahora verifican si las incidencias se identificaron, documentaron y cerraron de forma efectiva. Ya no se centran solo en si existen procedimientos; eval\u00faan si el sistema funciona seg\u00fan lo previsto.<br>Las acciones de auditor\u00eda incompletas o no verificadas pueden aumentar el riesgo de inspecci\u00f3n. ","inLanguage":"es"},"inLanguage":"es"},{"@type":"Question","@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601252435","position":5,"url":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601252435","name":"\u00bfQu\u00e9 registros est\u00e1n recibiendo ahora mayor escrutinio durante las inspecciones de la FDA?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"La FDA ahora pone mayor escrutinio en:<br>- Informes de auditor\u00eda interna y de proveedores<br>- Documentaci\u00f3n de revisi\u00f3n por la direcci\u00f3n<br>- Registros de trazabilidad de controles de dise\u00f1o<br>- Procedimientos CAPA y comprobaciones de eficacia<br>Seg\u00fan la experiencia en inspecciones, la verificaci\u00f3n de eficacia de CAPA es un punto d\u00e9bil frecuente. Las empresas suelen implementar acciones correctivas, pero no documentan evidencia objetiva de que la acci\u00f3n resolvi\u00f3 la causa ra\u00edz.<br>Bajo la QMSR, la eficacia importa tanto como la documentaci\u00f3n. ","inLanguage":"es"},"inLanguage":"es"},{"@type":"Question","@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601274703","position":6,"url":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601274703","name":"\u00bfPor qu\u00e9 las empresas que superaron MDSAP siguen recibiendo observaciones FDA 483?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Porque MDSAP y las inspecciones de la FDA tienen finalidades distintas. MDSAP eval\u00faa la conformidad. Las inspecciones de la FDA eval\u00faan el cumplimiento legal y el riesgo para la salud p\u00fablica. Los investigadores de la FDA no est\u00e1n sujetos a los m\u00e9todos de muestreo ni al alcance de auditor\u00eda de MDSAP. Si los inspectores identifican CAPA ineficaz, trazabilidad d\u00e9bil o brechas entre los procedimientos y la pr\u00e1ctica real, pueden emitir observaciones en el Formulario 483, incluso tras una auditor\u00eda MDSAP satisfactoria.    ","inLanguage":"es"},"inLanguage":"es"},{"@type":"Question","@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601293741","position":7,"url":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1771601293741","name":"\u00bfC\u00f3mo deber\u00edan prepararse los fabricantes para las inspecciones de la FDA bajo la QMSR?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Empiece pronto. La preparaci\u00f3n suele llevar m\u00e1s tiempo del esperado. Despu\u00e9s, realice una evaluaci\u00f3n estructurada de brechas de la QMSR. El cumplimiento con ISO 13485 por s\u00ed solo no confirma la alineaci\u00f3n completa con la FDA. Por \u00faltimo, forme a los equipos en el Compliance Program 7382.850. Las entrevistas simuladas y las simulaciones de inspecci\u00f3n ayudan a identificar debilidades. Incluso una remediaci\u00f3n documentada en curso demuestra control del sistema y reduce el riesgo de inspecci\u00f3n.      ","inLanguage":"es"},"inLanguage":"es"},{"@type":"Question","@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1772817091955","position":8,"url":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1772817091955","name":"\u00bfCu\u00e1ndo comienza la aplicaci\u00f3n de la FDA QMSR?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"La aplicaci\u00f3n de la FDA QMSR comenz\u00f3 el 2 de febrero de 2026, cuando la nueva Quality Management System Regulation sustituy\u00f3 oficialmente a la anterior Quality System Regulation (21 CFR Part 820). A partir de esa fecha, las inspecciones de la FDA operan bajo el Compliance Program 7382.850. ","inLanguage":"es"},"inLanguage":"es"},{"@type":"Question","@id":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1772817100964","position":9,"url":"https:\/\/mdxcro.com\/es\/fda-qmsr-regulacion-sistema-gestion-calidad\/#faq-question-1772817100964","name":"\u00bfCu\u00e1les son los requisitos de armonizaci\u00f3n entre la FDA QMSR y la ISO 13485 para 2026?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Bajo la QMSR de 2026, la ISO 13485:2016 se incorpora por referencia a la legislaci\u00f3n estadounidense. Esto significa que los fabricantes deben cumplir los requisitos de la ISO 13485 como parte del cumplimiento con la FDA. Sin embargo, la armonizaci\u00f3n no es una equivalencia completa: las obligaciones espec\u00edficas de la FDA, como UDI, notificaci\u00f3n MDR, registro\/listado de dispositivos y controles de etiquetado, siguen siendo plenamente exigibles y no est\u00e1n cubiertas \u00fanicamente por la ISO 13485. Consulte la tabla comparativa QSR vs QMSR vs ISO 13485 anterior para un desglose detallado.   ","inLanguage":"es"},"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/posts\/10285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/comments?post=10285"}],"version-history":[{"count":19,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/posts\/10285\/revisions"}],"predecessor-version":[{"id":12210,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/posts\/10285\/revisions\/12210"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/media\/10086"}],"wp:attachment":[{"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/media?parent=10285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/categories?post=10285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/tags?post=10285"},{"taxonomy":"resources-sector","embeddable":true,"href":"https:\/\/mdxcro.com\/es\/wp-json\/wp\/v2\/resources-sector?post=10285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}